Edwards Lifesciences (EW) Fundamentals 2026 — P/E 44.6x, Revenue Analysis | SniperIQ
Edwards Lifesciences (EW) is a US-listed Healthcare company in Medical - Devices with a market capitalization of $48.6B, trading at $84.33 on the NYSE. This SniperIQ fundamentals page covers Edwards Lifesciences's valuation (P/E 44.6x, P/B 4.7x), profitability (net margin 17.3%), revenue ($6.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Edwards Lifesciences's market cap?
Edwards Lifesciences (EW) has a market capitalization of approximately $48.6B, trading at $84.33 on the NYSE. Market cap moves with the live share price.
What is Edwards Lifesciences's P/E ratio?
Edwards Lifesciences's trailing twelve-month P/E ratio is 44.6x, with a price-to-book (P/B) of 4.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Edwards Lifesciences?
Edwards Lifesciences runs a net profit margin of 17.3%, a gross margin of 78.0%, and an operating margin of 27.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Edwards Lifesciences generate?
Edwards Lifesciences reported revenue of $6.1B for fiscal year 2025, with net income of
Does Edwards Lifesciences pay a dividend?
Edwards Lifesciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Edwards Lifesciences financially healthy?
Edwards Lifesciences carries a debt-to-equity ratio of 0.07x and a current ratio of 4.42x, with a market beta of 0.85. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Edwards Lifesciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Edwards Lifesciences (EW) the key facts are: market cap $48.6B, P/E 44.6x, revenue $6.1B, 52-week range 72.3-96.29. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Edwards Lifesciences's full fundamentals live
Get Edwards Lifesciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.